Compliance method
AssigneeNicoventures Trading Limited
InventorsMichael McEwan, George Grant Hardie, Oscar Camacho
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods incorporating the use of a biomarker (CEVal) for assessing compliance with a smoking cessation program, for example, a smoking cessation program which involves subjects switching from conventional cigarettes to a hybrid device, an e-cigarette and/or a tobacco heating product, a smoking cessation program involving the use of nicotine replacement therapy, a smoking cessation program involving lifestyle choices or therapy, or a combination thereof.
Claims10
A method of assessing compliance with a smoking cessation program, said method comprising:
- (a) providing one or more blood samples from a subject;
- (b) measuring the level of N-(2-cyanoethyl) valine (CEVal) from the one or more blood samples of the subject in a biological assay;
- (c) comparing the level obtained in step (b) with reference levels of CEVal for the smoking cessation program;
- and
- (d) stratifying the subject according to compliance with the smoking cessation program based on the comparison in step (c);
- and
- (e) modifying or maintaining the smoking cessation program for the subject based on the stratification in step (d);
- wherein the smoking cessation program comprises switching from combustible smoking articles to a non-combustible aerosol provision system, nicotine replacement therapy, lifestyle choices, therapy or a combination thereof;
- wherein the reference levels of CEVal are indicative of compliance or non-compliance with the smoking cessation program, or indicative of compliance, partial compliance or non-compliance with the smoking cessation program;
- wherein the smoking cessation program has a length of at least 80 days and wherein the reference CEVal levels at about day 80 to about day 100 of the smoking cessation program are:
- i. <about 78 to <about 40 pmol/g Hb CEVal for compliance;
- and
- ii. ≥60 to ≥about 78 pmol/g Hb CEVal for non-compliance;
- provided that (i) and (ii) are different;
- or
- i. <about 78 to <about 40 pmol/g Hb CEVal for compliance;
- ii. between about 60 and about 164 pmol/g Hb CEVal for partial compliance;
- and
- iii. >about 78 to >about 164 pmol/g Hb CEVal for non-compliance;
- provided that (i), (ii) and (iii) are different.
A method of assessing compliance with a smoking cessation program, said method comprising:
- (a) providing one or more blood samples from a subject;
- (b) measuring the level of N-(2-cyanoethyl) valine (CEVal) from the one or more blood samples of the subject in a biological assay;
- (c) comparing the level obtained in step (b) with reference levels of CEVal for the smoking cessation program;
- (d) stratifying the subject according to compliance with the smoking cessation program based on the comparison in step (c);
- and
- (e) modifying or maintaining the smoking cessation program for the subject based on the stratification in step (d);
- wherein the smoking cessation program comprises switching from combustible smoking articles to a non-combustible aerosol provision system, nicotine replacement therapy, lifestyle choices, therapy or a combination thereof;
- wherein the reference levels of CEVal are indicative of compliance or non-compliance with the smoking cessation program, or indicative of compliance, partial compliance or non-compliance with the smoking cessation program;
- wherein the smoking cessation program has a length of at least 80 days and wherein the reference CEVal levels at about day 80 to about day 100 of the smoking cessation program are:
- i. <about 78 to <about 40 pmol/g Hb CEVal for compliance;
- ii. between about 60 and about 150 pmol/g Hb CEVal for partial compliance;
- and
- iii. >about 78 to >about 150 pmol/g Hb CEVal for non-compliance;
- provided that (i), (ii) and (iii) are different.
Dependencies are inferred from the claim text.